Astellas Pharma Overview
- Status
-
Public
- Employees
-
14,754
- Stock Symbol
-
4503
- Investments
-
43
- Share Price
-
$9.38
- (As of Friday Closing)
Astellas Pharma General Information
Description
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Contact Information
Website
www.astellas.comCorporate Office
- 2-5-1, Nihonbashi-Honcho
- Chuo-ku
- Tokyo, 103-8411
- Japan
Corporate Office
- 2-5-1, Nihonbashi-Honcho
- Chuo-ku
- Tokyo, 103-8411
- Japan
Astellas Pharma Stock Performance
As of 16-May-2025, Astellas Pharma’s stock price is $9.38. Its current market cap is $16.8B with 1.79B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.38 | $9.14 | $8.53 - $12.77 | $16.8B | 1.79B | 6.81M | $0.19 |
Astellas Pharma Financials Summary
As of 31-Mar-2025, Astellas Pharma has a trailing 12-month revenue of $12.5B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
|---|---|---|---|---|
| EV | 21,780,880 | 21,780,880 | 23,623,976 | 25,100,359 |
| Revenue | 12,541,003 | 12,541,003 | 11,098,857 | 11,217,304 |
| EBITDA | 1,575,047 | 1,575,047 | 1,269,010 | 1,763,664 |
| Net Income | 332,799 | 332,799 | 117,967 | 729,153 |
| Total Assets | 22,316,837 | 22,316,837 | 23,585,088 | 18,435,922 |
| Total Debt | 5,556,087 | 5,556,087 | 6,078,732 | 938,112 |
Astellas Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Astellas Pharma Comparisons
Industry
Financing
Details
Astellas Pharma Competitors (55)
One of Astellas Pharma’s 55 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India |
Astellas Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Astellas Pharma Patents
Astellas Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12097189-B1 | Pharmaceutical composition for modified release | Active | 09-Feb-2024 | ||
| AU-2023419440-A1 | Engineered natural killer cells and related methods | Pending | 29-Dec-2022 | ||
| AU-2023413061-A1 | Pharmaceutical compositions for delivery to the eye | Pending | 23-Dec-2022 | ||
| AU-2023393653-A1 | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors | Pending | 14-Dec-2022 | ||
| US-20250025567-A1 | Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound | Pending | 31-Oct-2022 | A61K47/6849 |
Astellas Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Astellas Pharma Investments & Acquisitions (43)
Astellas Pharma’s most recent deal was a Joint Venture with Cell Therapy Manufacturing Platform (Astellas Pharma / Yaskawa Electric). The deal was made on 05-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cell Therapy Manufacturing Platform (Astellas Pharma / Yaskawa Electric) | 05-Mar-2025 | Joint Venture | Biotechnology | ||
| AviadoBio | 08-Oct-2024 | Later Stage VC | Drug Discovery | ||
| Ciconia Bioventures | 01-Aug-2024 | Joint Venture | Drug Discovery | ||
| Propella Therapeutics | 21-Dec-2023 | Merger/Acquisition | Biotechnology | ||
| Poseida Therapeutics | 07-Aug-2023 | PIPE | Biotechnology |
Astellas Pharma ESG
Risk Overview
Risk Rating
Updated April, 25, 2025
22.45 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Astellas Pharma Exits (10)
Astellas Pharma’s most recent exit was on 07-Aug-2023 from Poseida Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Poseida Therapeutics | 07-Aug-2023 | Completed |
|
||
| Kanyos Bio | 02-Jun-2015 | Completed |
|
||
| Kanyos Bio | 29-May-2015 | Completed |
|
||
| UMN Pharma | 17-Oct-2013 | Completed |
|
||
| Amgen Astellas BioPharma | 01-Oct-2013 | Joint Venture | Completed |
|
Astellas Pharma Affiliates
Subsidiaries (12)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Xyphos Biosciences | South San Francisco, CA | 2017 | |
| Potenza Therapeutics | Cambridge, MA | 2014 | |
| Universal Cells | Seattle, WA | 2013 | |
| Nanna Therapeutics | Cambridge, United Kingdom | 2012 | |
| Mitobridge | Cambridge, MA | 2011 |
Astellas Pharma FAQs
-
Where is Astellas Pharma headquartered?
Astellas Pharma is headquartered in Tokyo, Japan.
-
What is the size of Astellas Pharma?
Astellas Pharma has 14,754 total employees.
-
What industry is Astellas Pharma in?
Astellas Pharma’s primary industry is Pharmaceuticals.
-
Is Astellas Pharma a private or public company?
Astellas Pharma is a Public company.
-
What is Astellas Pharma’s stock symbol?
The ticker symbol for Astellas Pharma is 4503.
-
What is the current stock price of Astellas Pharma?
As of 16-May-2025 the stock price of Astellas Pharma is $9.38.
-
What is the current market cap of Astellas Pharma?
The current market capitalization of Astellas Pharma is $16.8B.
-
What is Astellas Pharma’s current revenue?
The trailing twelve month revenue for Astellas Pharma is $12.5B.
-
Who are Astellas Pharma’s competitors?
Biocon, Intas Pharmaceuticals, AbbVie, Merck & Co., and Glenmark Pharmaceuticals are some of the 55 competitors of Astellas Pharma.
-
What is Astellas Pharma’s annual earnings per share (EPS)?
Astellas Pharma’s EPS for 12 months was $0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
